Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
16 October 2020Website:
http://www.aligos.comNext earnings report:
N/ALast dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 01 Nov 2024 22:29:44 GMTDividend
Analysts recommendations
Institutional Ownership
ALGS Latest News
SOUTH SAN FRANCISCO, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of David Perry as Vice President of Business Development, effective immediately.
Here is how Aligos Therapeutics, Inc. (ALGS) and Clover Health Investments, Corp. (CLOV) have performed compared to their sector so far this year.
The average of price targets set by Wall Street analysts indicates a potential upside of 648.1% in Aligos Therapeutics (ALGS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Aligos Therapeutics (ALGS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
SOUTH SAN FRANCISCO, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, the “Company”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced the appointment of Heather Preston, M.D. and Margarita Chavez, J.D. as Class II Independent Directors to the Board of Directors, effective August 7, 2024. Dr. Preston will join the Nominating and Corporate Governance Committee as Chair and Ms. Chavez will join the Audit Committee.
SOUTH SAN FRANCISCO, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced positive data from six poster presentations at the European Association for the Study of the Liver (EASL) Congress 2024, being held June 5-8 in Milan, Italy.
Aligos Therapeutics (ALGS) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
SOUTH SAN FRANCISCO, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced six abstracts have been accepted for poster presentations, including two Top abstracts, at the European Association for the Study of the Liver (EASL) Congress 2024, being held June 5-8 in Milan, Italy. The abstracts released today can be found on the EASL website at www.easlcongress.eu.
After reaching an important support level, Aligos Therapeutics, Inc. (ALGS) could be a good stock pick from a technical perspective. ALGS recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.
Here is how Aligos Therapeutics, Inc. (ALGS) and Allogene Therapeutics (ALLO) have performed compared to their sector so far this year.
What type of business is Aligos Therapeutics?
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. It also has a clinical collaboration with Xiamen Amoytop Biotech Co., Ltd. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
What sector is Aligos Therapeutics in?
Aligos Therapeutics is in the Healthcare sector
What industry is Aligos Therapeutics in?
Aligos Therapeutics is in the Biotechnology industry
What country is Aligos Therapeutics from?
Aligos Therapeutics is headquartered in United States
When did Aligos Therapeutics go public?
Aligos Therapeutics initial public offering (IPO) was on 16 October 2020
What is Aligos Therapeutics website?
https://www.aligos.com
Is Aligos Therapeutics in the S&P 500?
No, Aligos Therapeutics is not included in the S&P 500 index
Is Aligos Therapeutics in the NASDAQ 100?
No, Aligos Therapeutics is not included in the NASDAQ 100 index
Is Aligos Therapeutics in the Dow Jones?
No, Aligos Therapeutics is not included in the Dow Jones index
When was Aligos Therapeutics the previous earnings report?
No data
When does Aligos Therapeutics earnings report?
Next earnings report date is not announced yet